Lisdexamfetamine

Lisdexamfetamine
Systematic (IUPAC) name
(2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a607047
Pregnancy cat. C
Legal status Schedule II (US)
Routes Oral
Pharmacokinetic data
Bioavailability 28%
Metabolism Gastro-intestinal (initial); Hepatic (extensively CYP2D6) after conversion to d-amphetamine
Half-life < 1 hour (prodrug molecule), 12-13 hours (d-amphetamine)
Excretion Renal: ~2%
Identifiers
CAS number 608137-32-2 Y
ATC code N06BA12
PubChem CID 11597698
DrugBank DB01255
ChemSpider 9772458 Y
UNII H645GUL8KJ Y
ChEMBL CHEMBL1201222 N
Synonyms (S)-2,6-diamino-N-[(S)-1-phenylpropan-2-yl]hexanamide
Chemical data
Formula C15H25N3O 
Mol. mass 263.378 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Lisdexamphetamine (L-lysine-D-amphetamine; sold as Vyvanse) is a psychostimulant prodrug of the phenethylamine and amphetamine chemical classes. Its molecular structure consists of dextroamphetamine coupled with the essential amino acid L-lysine.

Lisdexamfetamine itself is inactive and acts as a prodrug to dextroamphetamine upon cleavage of the lysine portion of the molecule. It was developed for the intention of creating a longer-lasting and more difficult to abuse version of dextroamphetamine, as the requirement of conversion into dextroamphetamine via enzymes in the red blood cells increases its duration, regardless of the route of ingestion.[1] There is no increased onset or effect as occurs with IV administration of dextroamphetamine compared to oral use of the same. Intravenously administered lisdexamfetamine produced likability effects similar to placebo, therefore affirming the drug's ability to reduce abuse potential.[2]

Lisdexamfetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children six to twelve years and in adults as an integral part of a total treatment program that may include other measures (i.e., psychological, educational, social). The safety and efficacy of lisdexamfetamine dimesylate in patients three to five years old have not been established.[3]

As opposed to Adderall, which contains roughly 75% dextroamphetamine and 25% levoamphetamine, lisdexamfetamine is a single-enantiomer (dextro) amphetamine formula. This pure formulation may reduce side effects, but certain individuals exhibit a better clinical response to the mixed isomer preparation.[4]

Vyvanse is also being investigated for possible treatment of Major Depressive Disorder, cognitive impairment associated with Schizophrenia, Excessive Daytime Sleepiness, and Binge Eating Disorder.[5]

Contents

Dosage

Lisdexamfetamine is available under the brand-name Vyvanse. Vyvanse comes in several different dosages (see table below). These dosages are usually labeled to be taken once daily.[6]

Vyvanse dosage strengths available[6]
Strength Appearance Imprint (unique label)
20 milligrams Capsule with ivory colored body and cap NRP104 or S489 20 mg
30 milligrams Capsule with white colored body and orange colored cap NRP104 or S489 30 mg
40 milligrams Capsule with white colored body and teal colored cap NRP104 or S489 40 mg
50 milligrams Capsule with white colored body and blue colored cap NRP104 or S489 50 mg
60 milligrams Capsule with aqua blue colored body and cap NRP104 or S489 60 mg
70 milligrams Capsule with blue colored body and orange colored cap NRP104 or S489 70 mg

25 mg of Vyvanse is molecularly equivalent to a 10 mg Dexedrine Spansule (both are about 7.425 mg dextroamphetamine base), although a 25 mg Vyvanse capsule is not commercially available.[7] However, the molecular equivalence ratio does not mean that the respective doses of Vyvanse and Adderall XR (Spansule) are bioequivalent because the two formulations have slightly different pharmacokinetic profiles. For example, while the area under the curve for the aforementioned pharmaceuticals is equivalent, the peak exposure (Cmax) to the active compound dextroamphetamine is about 50% higher for Vyvanse than for Dexedrine XR.[7] The conversion rate of lisdexamfetamine to dextroamphetamine base is 0.2948[8], meaning that each milligram of lisdexamphetamine is equivalent to 0.2948 mg of dextroamphetamine base.

History

Vyvanse was developed by New River Pharmaceuticals, who were bought by Shire Pharmaceuticals shortly before lisdexamfetamine began being marketed. Vyvanse is approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention-deficit hyperactivity disorder.

On April 23, 2008, Vyvanse received FDA approval for the adult population [9]. In a randomized, double-blind, four-week phase III trial in adult patients with ADHD, 30, 50 or 70mg/day of oral lisdexamfetamine caused a significantly greater improvement in ADHD-Rating Scale total score than placebo.[10]

On February 19, 2009, Health Canada approved 30 mg and 50 mg capsules of lisdexamphetamine for treatment of ADHD.[11]

Misuse potential

Lisdexamfetamine has less potential for misuse than its active metabolite (dextroamphetamine) due to being initially inactive upon consumption via all methods and taking longer to metabolise than dextro-amphetamine (both results of being a pro-drug). Misuse of lisdexamfetamine may cause the same extent of cardiovascular side-effects as dextro-amphetamine, but again this risk is likely to be reduced due to the method of administration.

Common side effects

Common side effects (side effects that have average rates of presentation; usually presenting in >5% of patients) of lisdexamfetamine use include: [6][12]

Severe side effects

Very infrequent but possibly severe side effects requiring immediate medical attention may be caused by lisdexamfetamine; these serious reactions include:[6][12]

See also

References